Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma × cabozantinib × Clear all

Phase

Phase 3 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 6 Multiple Myeloma 2 Carcinoma, Hepatocellular 2 Urothelial Cancer 1 Urologic Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Neuroendocrine Tumors 1 Kidney Neoplasms 1 Kidney Diseases 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

pembrolizumab 11 Cetuximab 5 Paclitaxel 4 durvalumab 3 Nivolumab 3 Gemcitabine 3 Cyclophosphamide 3 Cisplatin 3 poly ICLC 2 avelumab 2 Irinotecan 2 Ipilimumab 2 Carboplatin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 vistusertib 1 tislelizumab 1 tirbanibulin 1 spartalizumab 1 sonidegib 1 sitravatinib 1 repotrectinib 1 pralsetinib 1 pertuzumab 1 pepinemab 1 obinutuzumab 1 mogamulizumab 1 lutetium Lu 177 dotatate 1 lenvatinib 1 gedatolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡